UROwebinar: Perioperative treatment of cisplatin-eligible MIBC: The emerging role of EV–pembrolizumab
The perioperative treatment landscape for cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC) is rapidly evolving. This UROwebinar by the European School of Urology and the EAU Section of Oncological Urology will review the current available evidence following ESMO 2026
| Organiser | European School of Urology |
|---|---|
| CME | To be approved |
| Location | Online |
The UROwebinar will have a particular emphasis on perioperative enfortumab vedotin plus pembrolizumab and the KEYNOTE-B15/EV-304 trial, placing these findings within the broader context of cisplatin-based chemotherapy and chemoimmunotherapy.
Using a case-based multidisciplinary format, the experts will explore patient selection, treatment counselling, toxicity management, and integration with radical cystectomy. They will focus on interpreting trial endpoints, assessing applicability to routine practice, and coordinating care to optimize oncological outcomes while preserving surgical readiness.
Faculty
Dr. M.C. Mir Maresma (US)
Dr. L. Afferi (AU)
